JP2016540798A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540798A5
JP2016540798A5 JP2016540038A JP2016540038A JP2016540798A5 JP 2016540798 A5 JP2016540798 A5 JP 2016540798A5 JP 2016540038 A JP2016540038 A JP 2016540038A JP 2016540038 A JP2016540038 A JP 2016540038A JP 2016540798 A5 JP2016540798 A5 JP 2016540798A5
Authority
JP
Japan
Prior art keywords
opioid
active ingredient
pharmacologically active
nsaid
cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540798A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077748 external-priority patent/WO2015091352A1/en
Publication of JP2016540798A publication Critical patent/JP2016540798A/ja
Publication of JP2016540798A5 publication Critical patent/JP2016540798A5/ja
Pending legal-status Critical Current

Links

JP2016540038A 2013-12-16 2014-12-15 共押出により製造される、二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ ｒｅｓｉｓｔａｎｔ）剤形 Pending JP2016540798A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197503 2013-12-16
EP13197503.9 2013-12-16
PCT/EP2014/077748 WO2015091352A1 (en) 2013-12-16 2014-12-15 Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019107622A Division JP2019172688A (ja) 2013-12-16 2019-06-10 共押出により製造される、二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ ｒｅｓｉｓｔａｎｔ）剤形

Publications (2)

Publication Number Publication Date
JP2016540798A JP2016540798A (ja) 2016-12-28
JP2016540798A5 true JP2016540798A5 (enExample) 2018-12-06

Family

ID=49882823

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016540038A Pending JP2016540798A (ja) 2013-12-16 2014-12-15 共押出により製造される、二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ ｒｅｓｉｓｔａｎｔ）剤形
JP2019107622A Withdrawn JP2019172688A (ja) 2013-12-16 2019-06-10 共押出により製造される、二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ ｒｅｓｉｓｔａｎｔ）剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019107622A Withdrawn JP2019172688A (ja) 2013-12-16 2019-06-10 共押出により製造される、二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ ｒｅｓｉｓｔａｎｔ）剤形

Country Status (7)

Country Link
US (3) US20150164807A1 (enExample)
EP (1) EP3082781A1 (enExample)
JP (2) JP2016540798A (enExample)
AU (1) AU2014365038B2 (enExample)
CA (1) CA2933983A1 (enExample)
MX (1) MX2016007848A (enExample)
WO (1) WO2015091352A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502077D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd Improved hme technology

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
WO1999051208A1 (en) 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE602004025159D1 (de) 2003-03-26 2010-03-04 Egalet As Matrixzubereitungen für die kontrollierte Darreichung von Arzneistoffen
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
HRP20070456T3 (en) * 2003-08-06 2007-11-30 Grnenthal Gmbh Dosage form that is safeguarded from abuse
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1740156B8 (de) 2004-04-22 2012-07-11 Grünenthal GmbH Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform
EP1765298B1 (de) 2004-07-01 2012-10-24 Gruenenthal Gmbh Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders
PL1786403T3 (pl) 2004-07-01 2013-10-31 Gruenenthal Gmbh Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol
CA2572491A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
JP4563787B2 (ja) * 2004-12-10 2010-10-13 日立プラズマディスプレイ株式会社 プラズマディスプレイ装置及びその制御方法
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CA2611081C (en) 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
MX2008009267A (es) * 2006-01-21 2008-10-09 Abbott Gmbh & Co Kg Forma farmaceutica y metodo para la administracion de farmacos de abuso.
EP2104493A2 (en) 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2685118C (en) * 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
CN107028908A (zh) 2008-10-27 2017-08-11 阿尔扎公司 对乙酰氨基酚/曲马多口服延释剂型
EP2389169A1 (en) 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
EP2393487B1 (en) 2009-02-06 2016-11-02 Egalet Ltd. Pharmaceutical compositions resistant to abuse
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
PE20121067A1 (es) * 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
RS57913B1 (sr) * 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en) * 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc

Similar Documents

Publication Publication Date Title
JP2015147774A5 (enExample)
JP2013173781A5 (enExample)
JP2016503708A5 (enExample)
CN109843873A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
EP4249055A3 (en) Tofacitinib oral sustained release dosage forms
JP2013173782A5 (enExample)
JP2014237817A5 (enExample)
JP2017505494A5 (enExample)
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
WO2014153495A9 (en) Novel stat3 inhibitors
JP2017197541A5 (enExample)
JP2015529327A5 (enExample)
JP2017147380A5 (enExample)
JP2016540798A5 (enExample)
JP2017077228A5 (ja) 移動式搾乳装置および該移動式搾乳装置を使用した放牧方法
CN105764509A (zh) 达比加群酯或其盐的投药制剂及其制备方法
JP2019518052A5 (enExample)
JP2015208765A5 (enExample)
JP2014239805A5 (enExample)
刘倩君 Gable City
Puhr Finding Contentment Somewhere between Jean-Paul Sartre and the Huainanzi
宋炯炯 The First Piano Sonata of Rachmaninoff
张静利 A Study on The Construction of Corporate Citizenship Image in CSR Reports from The Perspective of Appraisal Theory
孙娟 Obama's First Speech in Shanghai
Kondowe Political Discourse Analysis: a Systemic Functional Study of Bingu Wa Mutharika's Inaugural Address